Outset Medical, Inc. (NASDAQ:OM) Given Average Rating of “Moderate Buy” by Analysts

Shares of Outset Medical, Inc. (NASDAQ:OM) have received a consensus recommendation of “Moderate Buy” from the six ratings firms that are currently covering the company, Marketbeat.com reports. One research analyst has rated the stock with a sell rating, one has assigned a hold rating, three have given a buy rating and one has given a strong buy rating to the company. The average 12 month target price among analysts that have updated their coverage on the stock in the last year is $10.00.

Several equities research analysts have recently commented on OM shares. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Outset Medical in a research report on Friday, March 27th. BTIG Research dropped their target price on shares of Outset Medical from $17.00 to $15.00 and set a “buy” rating for the company in a research report on Thursday, February 12th. TD Cowen reaffirmed a “buy” rating on shares of Outset Medical in a research report on Friday. Finally, Wall Street Zen cut shares of Outset Medical from a “hold” rating to a “sell” rating in a research report on Saturday, April 11th.

Hedge Funds Weigh In On Outset Medical

A number of institutional investors and hedge funds have recently made changes to their positions in OM. Legal & General Group Plc bought a new position in shares of Outset Medical during the second quarter valued at approximately $34,000. BNP Paribas Financial Markets increased its stake in shares of Outset Medical by 7,013.8% during the second quarter. BNP Paribas Financial Markets now owns 2,063 shares of the company’s stock valued at $40,000 after purchasing an additional 2,034 shares in the last quarter. New York State Common Retirement Fund bought a new position in shares of Outset Medical during the second quarter valued at approximately $108,000. Los Angeles Capital Management LLC bought a new position in shares of Outset Medical during the fourth quarter valued at approximately $29,000. Finally, Quantbot Technologies LP bought a new position in shares of Outset Medical during the second quarter valued at approximately $152,000.

Outset Medical Trading Down 21.2%

NASDAQ:OM opened at $3.69 on Tuesday. The company has a 50-day moving average price of $3.89 and a 200-day moving average price of $5.25. Outset Medical has a 12 month low of $3.00 and a 12 month high of $21.98. The company has a current ratio of 6.67, a quick ratio of 5.40 and a debt-to-equity ratio of 0.76. The stock has a market cap of $68.38 million, a price-to-earnings ratio of -0.89 and a beta of 1.92.

Outset Medical (NASDAQ:OM) last posted its earnings results on Thursday, May 7th. The company reported ($0.83) EPS for the quarter, missing the consensus estimate of ($0.79) by ($0.04). Outset Medical had a negative return on equity of 53.39% and a negative net margin of 63.65%.The company had revenue of $27.86 million during the quarter, compared to analysts’ expectations of $28.90 million. Equities analysts predict that Outset Medical will post -3.83 EPS for the current year.

About Outset Medical

Outset Medical is a medical technology company specializing in innovations for renal care. The company’s flagship offering, the Tablo Hemodialysis System, is designed to streamline and simplify dialysis treatment across acute and outpatient settings. By integrating water purification, dialysate production, and treatment monitoring into a single device, Tablo aims to reduce the complexity and logistical burden traditionally associated with hemodialysis therapy.

Tablo’s modular design allows for rapid setup and flexible deployment in hospitals, clinics, long‐term care facilities and emergency response scenarios.